Clinical Trial Update: Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. [Phase 2]

View source ↗

Summary

Phase 2 trial examining tucidinostat with metronomic capecitabine and endocrine therapy for advanced HR-positive, HER2-negative breast cancer after CDK4/6 inhib…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Endocrine therapy
• Tucidinostat (tucidinostat)
• capecitabine (metronomic) (capecitabine)

Snippet

Sponsor: wang shusen | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN